| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| CRIZOTINIB
| CRIZOTINIB | ANTINEOPLASTIC AGENTS | ORAL | F 43 PERCENT (250 MILLIGRAM) VD 1772 LITER (50 MILLIGRAM INTRAVENOUS) PPB 91 PERCENT Cl 60 LITER / HOUR (500 MILLIGRAM DAILY) HT 42 HOUR (250 MILLIGRAM) SOLUBILITY IN AQUEOUS MEDIA DECREASES OVER THE RANGE PH 1.6 TO PH 8.2 FROM GREATER THAN 10 MILLIGRAM / MILLILITER TO LESS THAN 0.1 MILLIGRAM / MILLILITER | TYROSINE KINASES ALK (IC50=24 NANOMOLAR) PMID22162641 C-MET PDB 5AAB (STRUCTURE OF C1156Y,L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB) LIGAND CODE = VGH (link to the list of PDB complexes) Download experimental 3D coordinates of VGH with added hydrogens | Hepatocyte growth factor receptor UNIPROT P08581 MET -- ALK tyrosine kinase receptor UNIPROT Q9UM73 ALK more at DrugCentral | EMA | |||
